Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JVK
|
|||
| Former ID |
DIB005557
|
|||
| Drug Name |
LY3090106
|
|||
| Synonyms |
Tibulizumab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0; ICD-9: 710.2] | Phase 2/3 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [2] | ||
| Company |
Eli lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04563195) BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01925157) A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.